ArticleAlzheimer's & dementia (New York, N. Y.)
How well is messaging about the importance of vaccination for people living with dementia being communicated? A jurisdictional scan of National Immunization Technical Advisory Groups and dementia advocacy organizations.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination is particularly important for people living with dementia (PLWD), who are at risk for meaningful declines in function and cognition after acute illnesses including vaccine-preventable infections. Even so, vaccine uptake remains suboptimal. Optimal tailoring of messaging relies on awareness in advisory, decision-making, and advocacy settings that PLWD are an important population for immunization. This policy forum paper discusses why vaccination is particularly important for PLWD and whether this is translated into public-facing and policy audience messaging. Jurisdictional scans investigated three questions: the inclusion of geriatrics expertise in a sample of eight National Immunization Technical Advisory Groups (NITAGs; Australia, Canada, France, Germany, Switzerland, the UK, United States, World Health Organization), whether PLWD are included in high-risk groups particularly recommended to receive adult vaccinations, and whether dementia advocacy organizations from these same jurisdictions discuss and recommend vaccination. We conclude that there remain important opportunities for improvement in understanding and communicating the benefits of vaccination for PLWD, and present policy recommendations for NITAGs, dementia advocacy organizations, and clinicians.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.